Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus- infected patients

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 7, 1999, Pages 1621-1630

  Lopez Ribot, Jose L ^a   McAtee, Robert K ^a   Perea, Sofia ^a   Kirkpatrick, William R ^a   Rinaldi, Michael G ^a,b   Patterson, Thomas F ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ENZYME; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LANOSTEROL; POSACONAZOLE; TERBINAFINE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CASE REPORT; DISEASE ASSOCIATION; FUNGUS CULTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DYNAMICS; NONHUMAN; OROPHARYNX; PRIORITY JOURNAL; PROTEIN EXPRESSION; YEAST;

EID: 0032779556     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.7.1621     Document Type: Article

References (38)

1. Albertson, G. D., M. Niimi, R. D. Cannon, and H. F. Jenkinson. 1996. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob. Agents Chemother. 40:2835-2841.
2. Challacombe, S. J. 1994. Immunological aspects of candidiasis. Med. Oral Pathol. 78:202-210.
3. Fling, M. E., J. Kopf, A. Tamrkin, J. A. Gorman, H. A. Smith, and Y. Koltin. 1991. Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate. Mol. Gen. Genet. 227:318-329.
4. Franz, R., S. L. Kelly, D. C. Lamb, D. E. Kelly, M. Ruhnke, and J. Morschhäuser. 1998. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob. Agents Chemother. 42:3065-3072.
5. Graybill, J. R., E. Montalbo, W. R. Kirkpatrick, M. F. Luther, S. G. Revankar, and T. F. Patterson. 1998. Fluconazole versus Candida albicans: a complex relationship. Antimicrob. Agents Chemother. 42:2938-2942.
6. Klein, R. S., A. H. Carol, C. B. Small, B. Moll, M. Lesser, and G. H. Friedland. 1984. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N. Engl. J. Med. 311: 354-3588.
7. Law, D., C. B. Moore, H. M. Wardle, L. A. Ganguli, M. G. L. Keaney, and D. W. Denning. 1994. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J. Antimicrob. Chemother. 34:659-668.
8. Lockhart, S. R., J. J. Fritch, A. S. Meier, K. Schröppel, T. Srikantha, R. Galask, and D. R. Soll. 1995. Colonizing populations of Candida albicans are clonal in origin but undergo microevolution through C1 fragment reorganization as demonstrated by DNA fingerprinting and C1 sequencing. J. Clin. Microbiol. 33:1501-1509.
9. Löffler, J., S. L. Kelly, H. Hebart, U. Schumacher, C. Lass-Flörl, and H. Einsele. 1997. Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol. Lett. 151:263-268.
10. López-Ribot, J. L., R. K. McAtee, L. N. Lee, W. R. Kirkpatrick, T. C. White, D. Sanglard, and T. F. Patterson. 1998. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother. 42:2932-2937.
11. Marcotte, H., and M. C. Lavoie. 1998. Oral microbial ecology and the role of salivary immunoglobulin A. Microbiol. Mol. Biol. Rev. 62:71-109.
12. Meunier, F. 1989. Candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. 8:438-447.
13. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard. NCCLS document M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
14. Patterson, T. F., W. R. Kirkpatrick, S. G. Revankar, R. K. McAtee, A. W. Fothergill, D. I. McCarthy, and M. G. Rinaldi. 1996. Comparative evaluation of macrodilution and chromogenic agar screening for determining fluconazole susceptibility of Candida albicans. J. Clin. Microbiol. 34:3237-3239.
15. Patterson, T. F., S. G. Revankar, W. R. Kirkpatrick, O. Dib, A. W. Fothergill, S. W. Redding, D. A. Sutton, and M. G. Rinaldi. 1996. Simple method for detecting fluconazole-resistant yeasts with chromogenic agar. J. Clin. Microbiol. 34:1794-1797.
16. Pfaller, M. A., J. H. Rex, and M. G. Rinaldi. 1997. Antifungal susceptibility testing: technical advances and potential clinical implications. Clin. Infect. Dis. 24:776-784.
17. Plettenberg, A., E. Reisinger, U. Lenzner, H. Listemann, M. Ernst, P. Kern, M. Dietrich, and W. Meigel. 1990. Oral candidosis in HIV-infected patients. Prognostic value and correlation with immunological parameters. Mycoses 33:421-425.
18. Powderly, W. G. 1994. Resistant candidiasis. AIDS Res. Hum. Retroviruses 10:925-929.
19. Prasad, R., W. P. De Wergifosse, A. Goffeau, and E. Balzi. 1995. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr. Genet. 27:320-329.
20. Revankar, S. G., W. R. Kirkpatrick, R. K. McAtee, O. P. Dib, A. W. Fothergill, S. W. Redding, D. A. McGough, M. G. Rinaldi, and T. F. Patterson. 1996. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in HIV-infected patients. J. Infect. Dis. 174:821-827.
21. Revankar, S. G., W. R. Kirkpatrick, R. K. McAtee, O. P. Dib, A. W. Fothergill, S. W. Redding, M. G. Rinaldi, and T. F. Patterson. 1998. A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in human immunodeficiency virus-infected patients: clinical outcomes and development of fluconazole resistance. Am. J. Med. 105:7-10.
22. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Berry. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
23. Rex, J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1-8.
24. Sambrook, J. F., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
25. Sanglard, D., F. Ischer, L. Koymans, and J. Bille. 1998. Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42:241-253.
26. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1996. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob. Agents Chemother. 40:2300-2305.
27. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143: 405-416.
28. Sanglard, D., K. Kuchler, F. Ischer, J.-L. Pagani, M. Monod, and J. Bille. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39:2378-2386.
29. Schmid, J., E. Voss, and D. R. Soll. 1990. Computer-assisted methods for assessing strain relatedness in Candida albicans by fingerprinting with the moderately repetitive sequence Ca3. J. Clin. Microbiol. 28:1236-1243.
30. Schoofs, A., F. C. Odds, R. Colebunders, M. Ieven, L. Wouters, and H. Goossens. 1997. Isolation of Candida species on media with and without added fluconazole reveals high variability in relative growth susceptibility phenotypes. Antimicrob. Agents Chemother. 41:1625-1635.
31. Takasuka, T., G. G. Baily, M. Birch, M. J. Anderson, D. Law, and D. W. Denning. 1998. Variation in morphotype, karyotype and DNA type of fluconazole resistant Candida albicans from an AIDS patient. J. Infect. 36:57-62.
32. Vanden Bossche, H., P. Marichal, and F. C. Odds. 1994. Molecular mechanisms of drug resistance in fungi. Trends Microbiol. 2:393-400.
33. Vanden Bossche, H., P. Marichal, J. Gorrens, D. Bellens, H. Moereels, and P. A. J. Janssen. 1990. Mutation in cytocrome P450-dependent 14α demethylase results in decreased affinity for azole antifungals. Biochem. Soc. Trans. 18:56-59.
34. Walsh, T. J., M. Kasai, A. Francesconi, D. Landsman, and J. Chanock. 1997. New evidence that Candida albicans possesses additional ATP-binding cassette MDR-like genes: implications for antifungal azole resistance. J. Med. Vet. Mycol. 35:133-137.
35. White, T. C. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41:1482-1487.
36. White, T. C. 1997. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14α demethylase in Candida albicans. Antimicrob. Agents Chemother. 41:1488-1494.
37. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
38. White, T. C., M. A. Pfaller, R. G. Rinaldi, J. Smith, and S. W. Redding. 1997. Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis. 3:S102-S109.